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Open access undThe efﬁcacy and mechanism of action of cisplatin and gemcitabine were investigated in a panel of neu-
roblastoma cell lines and multicellular tumor spheroids. In neuroblastoma spheroids, the combination of
cisplatin and gemcitabine induced a complete cytostasis at clinical relevant concentrations. A synergistic
effect was observed when cells were coincubated with both drugs or preincubated with gemcitabine ﬁrst.
These administration sequences resulted in NASS cells in decreased ERCC1 and XPA expression, two key
proteins of the NER DNA repair system, and increased platinum adduct formation in DNA. Most of these
phenomena were not observed in SJNB8 cells which might explain the lack of synergy between cisplatin
and gemcitabine in SJNB8 cells. Our results showed favorable interactions between cisplatin and gemcit-
abine in 4 out of 5 cell lines. Therefore, we feel that inclusion of gemcitabine into cisplatin-containing
regiments might be a promising new strategy for the treatment of neuroblastoma.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Neuroblastoma is the most common solid extra cranial malig-
nancy in children and is responsible for 15% of all childhood cancer
deaths. The 5-year survival rates among children with high-risk
neuroblastoma have shown only a modest improvement despite
an escalation in the intensity of the therapy provided [1], although
the addition of anti-GD2 to the treatment is promising [2]. Anti-
cancer agents are rarely used as single agents and effective chemo-
therapy usually depends on the identiﬁcation of suitable combina-
tions to treat a speciﬁc type of tumor. Therefore, there is an urgent
need to improve the efﬁcacy of currently applied chemotherapeu-
tic drugs in the treatment of neuroblastoma by introducing novel
combinations of agents which can overcome chemoresistance
and increase survival.
Gemcitabine (20,20-diﬂuoro-20-deoxycytidine, dFdC) is a deoxy-
cytidine analog that exerts its anti-tumor activity via multiple
mechanisms of action. dFdC undergoes intracellular phosphoryla-
tion to the active metabolites dFdC-diphosphate and dFdC-triphos-
phate, leading to inhibition of ribonucleotide reductase and
incorporation of dFdC-triphosphate into DNA and RNA [3]. Afterl Center, Laboratory Genetic
msterdam, The Netherlands.
B.P. van Kuilenburg).
er the Elsevier OA license.one moiety is incorporated into DNA, one more nucleotide is added
after which chain elongation stops, rendering the dFdC moiety
resistant to excision by DNA exonuclease activity [4]. dFdC has pro-
ven anti-tumor activity in vivo against human solid tumors [5,6].
Previously, it has been shown that neuroblastoma cells are highly
sensitive to dFdC in vitro and in animal models [7,8].
Platinum-containing drugs have a broad range of anti-tumor
activity in malignant disease and are used to treat many types of
cancer [9]. Cisplatin (cis-diamminedichloroplatinum(II), cddp) is a
DNA-damaging agent that forms platinum adducts in the DNA. This
leads to intrastrand and interstrand crosslinks which may cause
alteration in the structure of DNA [10]. Changes in the DNA helix
can be recognized and activateDNA repair systems, allowing the cell
to repair the damage. It has been suggested that both the nucleotide
excision repair (NER) and the mismatch repair (MMR) systems are
involved in mediating platinum resistance [11–13]. It was reported
before that dFdC could have an inhibiting effect on the expression of
key proteins involved in NER and MMR, thereby inhibiting repair of
DNA damage caused by cddp [14]. A number of copper transporters
have been shown to be involved in the uptake (hCTR1) and efﬂux
(ATP7A and ATP7B) of cddp [15,16]. Modulations in expression lev-
els of these transporters could, therefore, have an effect on the intra-
cellular platinum concentrations and thereby also be involved in
mediating platinum resistance.
Favorable interactions have been observed for cddp and dFdC in
solid tumors [17,18]. Because of their differentmechanism of action
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dates for combination therapy for the treatment of neuroblastoma.
In this study, we have performed an in-depth analysis of the ef-
fect of cddp and dFdC in a panel of neuroblastoma cell lines as well
as in spheroids, which are three dimensional aggregates of cancer
cells that, due to their cellular organization, have been shown to
resemble in vivo tumors with respect to growth rates and sensitiv-
ity towards chemotherapeutic drugs.2. Materials and methods
2.1. Drugs and chemicals
cis-Diamminedichloroplatinum (cddp, Cisplatin) was obtained from Pharm-
achemie (Haarlem, The Netherlands), 2,020-Diﬂuoro-20-deoxycytidine (dFdC or gem-
citabine) was obtained from Eli Lilly (Nieuwegein, The Netherlands). Both were
solubilized in phosphate-buffered saline (PBS) to a concentration of 3.3 mM and
1 mM, respectively. Final dilutions of both drugs were made in culture medium.
[3H]-20 ,20-diﬂuoro-20-deoxycytidine 14 Ci/mmol) was purchased fromMoravek Bio-
chemicals (Brea, CA) and [14C]Thymidine (Thd) (2.04 GBq/mmol) was obtained from
Amersham International (Buckinghamshire, UK). All other chemicals were of ana-
lytical grade and commercially available.2.2. Cell culture
Six MYCN single copy neuroblastoma cell lines (FISK, NASS, SY5Y, SK-N-SH, GI-
M-EN and SHEP2) and sixMYCN ampliﬁed neuroblastoma cell lines (SJNB8, SJNB10,
SK-N-BE, NGP, SJNB6 and IMR32.k1) were cultured as described before [19]. Spher-
oids of NASS and SJNB8 cell lines were prepared as described before [19] and trea-
ted with different concentrations cddp, dFdC or coincubated with both drugs for
2 weeks, without changing the culture medium. The experiments were performed
in quadruplicate. Spheroid size was monitored weekly by measurement of the
cross-sectional area of individual spheroids ﬁve-times magniﬁed photos using a
microscope.2.3. Measurement of cell viability and caspase-3 activity
Cells were plated in 96-well plates at a density of 3000–6000 cells per well,
depending on the cell line, in a total volume of 100 ll. Cells were allowed to adhere
overnight, after which the medium was replaced by medium containing different
concentrations of cddp, dFdC or a combination of both drugs. Three different coin-
cubation schedules were used: coincubation with both drugs for 72 h or preincuba-
tion with cddp or dFdC for 24 h followed by coincubation of both drugs for the next
48 h. After 24, 48 and 72 h MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymeth-
oxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) was added to the wells containing
medium with drugs and the viability of the cells was analysed (Promega, Madison,
WI, USA) according to the manufacturer’s protocol. Caspase-3 activation was mea-
sured by the caspase-glo 3/7 assay (Promega, Madison, WI, USA) according to the
manufacturer’s protocol.2.4. Multiple drug effect analysis
Various concentrations of cddp and dFdC were added in a ﬁxed IC50-based mo-
lar ratio (cddp:dFdC) of 120:1 for FISK and NASS, and 600:1 for SY5Y, SJNB8 and
SJNB10. The mode of interaction (synergy, antagonism or additivity) was deter-
mined by the combination index (CI), as described by Chou and Talalay [20] and
was calculated for each combination of cddp and dFdC using the Calcusyn computer
program (Biosoft, Ferguson, MO).2.5. Western blotting
Cells (attached and ﬂoating) were collected by trypsinization, centrifuged and
the pellet was washed twice in ice-cold PBS. Subsequently, cells were lysed in
RIPA-buffer (1% w/v NP40 (LKB-Produkter AB), 12.06 mM sodiumdeoxycholate (Sig-
ma), 0.1% w/v SDS (Roche) in PBS) completed with protease inhibitor cocktail
(Roche), 0.5 mM NaF and 0.5 mM Na3VO4. Protein concentrations were determined
using a BCA protein assay [21]. SDS–polyacrylamide gel electrophoresis was per-
formed, essentially as described by Laemmli [22] followed by Western blotting
using mouse anti-human poly (ADP-ribose) polymerase (PARP) monoclonal anti-
body 1:10,000 (Biomol, UK), XPA (sc-56813 clone 12F5) 1:2000, ERCC1 (sc-53281
clone 3H11) 1:200, MLH1 (sc-56159 clone 164C819) 1:1000 and MSH2 (sc-65942
clone 3A2B8C) 1:1000 (Santa Cruz, CA, USA). Antigen–antibody complexes were
visualized using horseradish peroxidase-conjugated secondary antibodies. Detec-
tion was carried out by ACL (Amersham) on a LAS3000 (Fujiﬁlm). Equal loading
was conﬁrmed using b-actin or a-tubulin.2.6. Extraction and analysis of radiolabeled nucleotides
Cells were seeded in six well plates at a density of 0.5  106 cells per well and
allowed to adhere overnight. The cells were preincubated with 0.25, 1 or 4 lM cddp
for 24 h, after which 50 nM [3H]dFdC and 250 nM [14C]Thymidine (Thd) were added
to the wells. After 3 h of incubation, the cells were extracted and analyzed as de-
scribed previously [23].
2.7. Platinum–DNA adduct measurement
Cells were seeded in 75 cm2 ﬂasks at a conﬂuency of approximately 20% and al-
lowed to adhere overnight. Medium was replaced by medium containing different
concentrations of cddp or dFdC or the coincubations as described above. After
24 hrs, cddp or dFdC was added to the cells preincubated with dFdC or cddp, respec-
tively, and incubated for 48 h. Subsequently, cells were harvested by trypsinization
and DNA was isolated using Wizard Genomic DNA Puriﬁcation (Promega) according
to the manufacturer’s protocol. DNA platination was measured using a previously
published method adapted for tumor cells [16].
2.8. Quantitative reverse transcription-PCR
Cells were seeded in six well plates at approximately 20% conﬂuency and al-
lowed to adhere overnight. Medium was replaced by medium containing cddp
and/or dFdC, using the coincubation schedules as described above. ATP7A, ATP7B
and CTR1 mRNA levels were measured using a quantitative PCR (qPCR) method of
detection of relative amounts of ﬁrst-strand cDNA. cDNA was generated from
mRNA isolated using Trizol (Invitrogen). qPCR was performed on a Roche Light-
Cycler 480 machine and data was analyzed by using LinReg [24]. The forward
and reverse primers for ATP7A, ATP7B and CTR1 were: ATP7A, 50-GAGA-
AAAGGTCGGACTGCTG-30 (forward) and 50-TGCCAACCTGAGAAGCAATAG-30 (re-
verse); ATP7B 50-TACCCATTGCAGCAGGTGTC-30 (forward) and 50-ACTTGAGCTGCA
GGGATGAG-30 (reverse); CTR1 50-AGCTGGAGAAATGGCTGGAG-30 (forward) and
50-AGGTGAGGAAAGCTCAGCATC-30 (reverse) [16]. Three independent sample sets
were analyzed, with experiments in each sample set being performed in triplicate.
2.9. Statistical analyses
Data were expressed as mean values ± SD, and statistical analyses were per-
formed by using GraphPad Prism (version 5.01).
3. Results
3.1. Effect of cddp and dFdC on viability and apoptosis in
neuroblastoma cells
The IC50 values for cddp and dFdC as a monodrug after 72 h
were determined in a panel of neuroblastoma cell lines growing
in monolayers, consisting of six MYCN single copy and six MYCN
ampliﬁed cell lines (Table 1). There was a tendency for MYCN
ampliﬁed cell lines to be more sensitive for dFdC compared to
MYCN single copy cell lines (P = 0.1). A difference in sensitivity to-
wards cddp between MYCN single copy and MYCN ampliﬁed cell
lines was not observed. Furthermore, cddp administered as a
monodrug or in combination with dFdC resulted in an increased
caspase-3 activity, reﬂecting the induction of apoptosis (Fig. 1), ex-
cept for SJNB10. Treatment of cells with dFdC for 24 h showed an
increased caspase-3 activity in SY5Y cells only, but not in other cell
lines tested. NASS and SJNB8 cells exposed to cddp or dFdC for 72 h
showed PARP cleavage, a marker of apoptosis (Fig. 2).
3.2. Synergism between cddp and dFdC dependent on administration
sequence
In 4 out of 5 cell lines an additive/synergistic effect for the drug
combination cddp–dFdC was observed, depending on the adminis-
tration sequence of the drugs (Fig. 3). In the NASS cell line a
synergistic effect was observed for the administration sequence
preincubation with dFdC followed by a coincubation with cddp
and dFdC for 72 h and coincubation with both drugs for 72 h. In
contrast, an antagonistic effect was observed when NASS cells
were preincubated with cddp prior to the administration of dFdC.
In SJNB8 cells an antagonistic effect of all combinations was
Table 1
IC50 concentrations ± SD of all cell lines.
Cell lines cddp (lM) dFdC (nM) Cell lines cddp (lM) dFdC (nM)
MYCN single copy MYCN ampliﬁed
FISK 2.1 ± 0.9 13.7 ± 6.9 SJNB8 6.0 ± 3.7 4.2 ± 1.4
NASS 3.2 ± 2.0 22.3 ± 2.3 SJNB10 2.3 ± 0.7 2.9 ± 0.5
SY5Y 1.2 ± 0.4 4.6 ± 1.7 SK-N-BE 2.3 ± 1.4 29.9 ± 7.7
SK-N-SH 1.4 ± 0.3 28.5 ± 5.1 NGP 1.9 ± 0.7 5.1 ± 1.7
GI-M-EN 2.7 ± 1.2 6.2 ± 0.6 SJNB6 3.8 ± 2.6 8.0 ± 7.4
SHEP2 8.4 ± 1.2 28.0 ± 2.0 IMR32.k1 0.8 ± 0.7 4.6 ± 1.5
Cells were treated with cddp or dFdC for 72 h.
Fig. 1. The effect of cddp and dFdC on apoptosis. Cells were treated with different concentrations of cddp, dFdC or the combination of both administrated at the same time for
24 h. Caspase-3 activity was measured and depicted as percentage compared to the untreated control. Each bar represents the mean ± SD of three experiments.
Fig. 2. PARP cleavage. NASS (A) and SJNB8 (B) neuroblastoma cells treated with different concentrations of cddp and dFdC for 72 h followed by analysis of PARP.
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drugs. In the remaining three cell lines, an additive to synergistic
effect was observed in case the cells were preincubated with dFdC
followed by the administration of cddp.
3.3. Effect of cddp and dFdC on neuroblastoma spheroids
The sensitivity for cddp and dFdC in SJNB8 spheroids was com-
parable to the sensitivity observed in cells growing in monolayer.
In contrast, NASS spheroids showed approximately a 10-fold in-
creased sensitivity for dFdC, and a comparable IC50 value for cddp.
Cytostasis was observed in spheroids treated with high concentra-
tions of the combination cddp–dFdC (Fig. 4), which was more pro-
found in NASS spheroids compared to SJNB8 spheroids.
3.4. Effect of cddp and dFdC on proteins involved in the NER and MMR
system
A downregulation of the expression of XPA and ERCC1, two key
proteins of the NER pathway, was observed in the NASS cell line ex-posed to cddp and dFdC as amonodrug or in combinationwith cddp.
The most profound effect was seen when cells were preincubated
with dFdC or coincubated with both drugs. This effect was not, or
to a lesser extent, observed in SJNB8 cells (Fig. 5). No differences in
the MLH1 and MSH2 expression were detected (data not shown).
3.5. The dFdC and thymidine incorporation into DNA
To study the growth-inhibiting effect of cddp and dFdC, [14C]Thd
and [3H]dFdC incorporation into DNA was measured. Pretreatment
of NASS and SJNB8 cells with cddp decreased the [14C]Thd incorpo-
ration into DNA in a concentration-dependent manner. The effect of
cddp on themaximal reduction of [14C]Thd incorporationwasmore
profound for NASS cells then for SJNB8, 90% and 60%, respec-
tively. On the contrary, cddp pretreated cells showed a slightly in-
creased [3H]dFdC incorporation in newly synthesized DNA
compared to cells treated with [3H]dFdC only (Fig. 6) The ratio
[3H]dFdC incorporation/[14C]Thd incorporation, reﬂecting the
amount of incorporated dFdC in newly synthesized DNA, was 1.8-
fold higher in NASS cells compared to SJNB8 (Table 2).
Fig. 3. Box plots of the combination index (CI) values of cddp and dFdC in ﬁve neuroblastoma cell lines. The top, bottom and line through the middle of a box correspond to
the 75th percentile, 25th percentile and 50th percentile, respectively. The whiskers on the bottom extend from the lowest value and top to the highest value. An average CI
was calculated from data points with FA (fraction affected) 0.6, 0.75 and 0.9. CI > 1.1, antagonism; 0.9–1.1, additive effect; <0.9, synergistic effect. The results shown are the
mean ± SD of at least four independent experiments.
Fig. 4. The effect of cddp and dFdC on spheroid growth. Spheroids were treated with cddp or dFdC, administered as monodrug or as a combination of both and photographed
weekly to monitor the increase of the area. Panel A shows NASS and SJNB8 spheroids treated with cddp and/or dFdC. Panel B shows the calculated area of spheroids treated
with different concentrations cddp and/or dFdC for 14 days, depicted as percentage compared to the untreated control. Each bar represents the mean area ± SD of four
experiments.
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After exposure of NASS and SJNB8 cells to increasing concentra-
tions of cddp, a dose-dependent increase of DNA platination wasobserved. In NASS cells, preincubation with 42 nM dFdC followed
by 5 lM cddp as well as coincubation with both drugs resulted
in an increase of 45% (P < 0.05) and 84% (P < 0.05), respectively in
platinum adduct formation in DNA compared to cells exposed to
Fig. 5. Immunoblot analysis of ERCC1 and XPA associated with cddp resistance. Blots show the changes in ERCC1 and XPA expression after treatment of (A) NASS
neuroblastoma cells and (B) SJNB8 neuroblastoma cells. Cells were treated for 72 h with different concentrations of cddp and dFdC and different administration sequences.
Fig. 6. The effect of dFdC and cddp on DNA synthesis. Cells were pretreated with 0, 0.25, 1 or 4 lM cddp for 21 h after which they were exposed to 250 nM [14C]Thd or 50 nM
[3H]dFdC for 3 h. The amount of [14C]Thd incorporated into DNA in untreated NASS and SJNB8 cells was 555 ± 4 fmol/lg protein and 584 ± 20 fmol/lg protein, respectively.
The amount of [3H]dFdC incorporated in NASS and SJNB8 cells, without prior incubation of cddp, was 1.7 ± 0.04 fmol/lg and 1.5 ± 0.05 fmol/lg protein, respectively. The
amount [14C]Thd incorporation was given as a percentage of untreated control cells. The incorporation of [3H]dFdC in the DNA was given as a percentage of cells treated with
[3H]dFdC only. The results shown are the mean ± SD of three independent experiments.
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decreased platinum adduct formation in DNA by approximately
22% (P = 0.19). In contrast, in SJNB8 cells, irrespective of the admin-
istration sequence used, the combination of cddp and dFdC re-
sulted in a decreased formation of platinum adducts in DNA
compared to cells treated with cddp only. Thus, the levels of plat-
inum adduct formation in DNA are in line with the degree of tox-
icity observed after treatment of NASS and SJNB8 cells with the
combination cddp–dFdC.Table 2
Ratio of [3H]dFdC incorporation/[14C]Thd incorporation.
Cell line 0 lM 0.25 lM 1 lM 4 lM
Concentration cddp (lM)
NASS 100 150 240 480
SJNB8 100 110 140 260
Ratio of [3H]dFdC incorporation/[14C]Thd incorporation in NASS and SJNB8 cell lines
exposed to an increasing cddp concentration. The [3H]dFdC incorporation/[14C]Thd
incorporation ratio of cells exposed to 50 nM dFdC was set to 100%. Cells were
pretreated with 0, 0.25, 1 or 4 lM cddp for 21 h after which they were exposed to
250 nM [14C]Thd or 50 nM [3H]dFdC for 3 h.3.7. Gene expression analysis of CTR1, ATP7A and ATP7B
Exposure of neuroblastoma cells to dFdC as a monodrug or in
combination with cddp resulted in a downregulation of the expres-
sion of the copper efﬂux transporter ATP7A in NASS cells (P < 0.05)
which was not observed in SJNB8 cells (Fig. 8). An upregulation of
the expression of the copper uptake transporter hCTRwas observed
in NASS cells preincubated with dFdC (P < 0.05) which was also not
observed in SJNB8 cells. NASS cells pretreated with cddp resulted
in a decreased expression of the copper efﬂux transporter ATP7B.4. Discussion
The favorable interactions which have been observed for cddp
and dFdC in some solid tumors prompted us to explore the effect
of the interaction between cddp and dFdC in a panel of neuroblas-
toma cell lines. Due to the heterogeneity of neuroblastoma, we
have investigated the effectiveness of this combination in a panel
of ﬁve neuroblastoma cell lines.
BothMYCN ampliﬁed and MYCN single copy neuroblastoma cell
lines proved to be highly sensitive towards dFdC with IC50 values in
Fig. 7. Platinum content in DNA. The amount of platinum adduct formation in DNA was determined after (A) incubation with cddp alone for 72 h, (B) preincubation for 24 h
with cddp followed by 48 h coincubation with dFdC, (C) 72 h of coincubation with cddp and dFdC, (D) incubation with cddp alone for 48 h and after (E) preincubation for 24 h
with dFdC followed by 48 h coincubation with cddp. Administration sequences (A–C) were exposed to cddp for 72 h. Since administration sequence (E) had an exposure for
48 h to cddp, this should be compared to (D). Platinum adducts are depicted as adducts per million nucleotides in NASS and SJNB8 cells. The results shown are the mean ± SD
of three independent experiments.
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more sensitive for dFdC compared to MYCN single copy cell lines,
which has been described before [7,25]. dFdC is a pro-drug that
has to be activated by phosphorylation to be therapeutically effec-
tive. In particularly, the incorporation of dFdC into DNA has pro-
found effects on DNA synthesis. This phenomenon might explain
the observation that only minimal toxicity was observed after
24 h whereas profound apoptosis was detected after 72 h of incu-
bation with dFdC. The high sensitivity of neuroblastoma cells to-
wards dFdC might be due to the high activity of the anabolic
enzyme deoxycytidine kinase and the low activity of the inactivat-
ing enzyme cytidine deaminase in neuroblastoma [8].
In neuroblastoma spheroids, cddp and dFdC induced a complete
cytostasis at clinical relevant concentrations (2.5 lM and 1.25 nM,
respectively). Peak plasma levels (PPL) for cddp between 6 and
12 lM were measured in neuroblastoma patients after initial che-
motherapy [26]. PPL for dFdC in neuroblastoma patients are not
known but a study performed in adult patients with refractory so-
lid cancer, PPL between 2 and 512 lM, depending on the dose
administered, were reached [27].
It has been shown that overexpression of NER genes is associ-
ated with cddp resistance in ovarian, glioma, bladder and lung can-
cer cells [28]. The most profound inhibition of the ERCC1 and XPA,
two proteins which play a key role in the NER system, was ob-
served after exposure of NASS cells to dFdC, cddp, cells preincu-
bated for 24 h with dFdC, or cddp and dFdC administrated at the
same time. These phenomena were not observed in SJNB8 cells,
which could explain the synergistic effect and antagonistic effect
between cddp and dFdC in NASS and SJNB8 cells, respectively.
In addition, an increase in the formation of DNA platinum ad-
ducts was observed when NASS cells were exposed simultaneously
to dFdC and cddp or when cells were preincubated with dFdC
followed by the addition of cddp. This observation is in accordancewith results of previous studies obtained in human ovarian cancer
cell lines [14,29,30]. The increase in platinum adducts in DNA
could be related to the inhibition of the NER system by dFdC, which
has been described before, thereby inhibiting the removal and re-
pair of the platinum adducts [31].
It has been reported that the copper uptake transporter hCTR1
and copper efﬂux transporters ATP7A and ATP7B are involved in
cddp sensitivity or resistance [15,16,32]. Our results showed a
down regulating effect of dFdC on ATP7A and ATP7B and an upreg-
ulating effect of hCTR gene expression in NASS cells only. This phe-
nomenonmight also contribute to the observed synergistic toxicity
of cddp and dFdC based treatment in NASS cells. It has to be men-
tioned that the expression of the ATP7B transporter is 50 times
lower compared to ATP7A.
Exposing NASS or SJNB8 neuroblastoma cells to cddp resulted in
a profound inhibition of DNA synthesis. The inhibiting effect of
cddp on DNA synthesis when cells are pre-exposed to cddp could
be a possible explanation for the tendency for this administration
sequence to be antagonistic, since dFdC needs to be incorporated
into DNA before it can exerts its cytotoxic effect. dFdC-triphos-
phate itself competes with the natural substrate dCTP for incorpo-
ration into DNA [4]. Furthermore, dFdC-diphosphate inhibits
ribonucleotide reductase, leading to depletion of the intracellular
dCTP pools and facilitating incorporation of dFdC-triphosphate into
DNA [33]. Furthermore, cddp has been shown to alter deoxynucle-
otide pools and this mechanism could be a conceivable explanation
as to why a slightly increased incorporation of dFdC into newly
synthesized DNA was observed in cddp pretreated cells [34].
Previously, the efﬁcacy and tolerability of dFdC administrated
as a monodrug in pretreated pediatric patients with refractory so-
lid tumors, including neuroblastoma, was determined. Although
there was a good tolerability there is probably no general relevance
in using dFdC as a monodrug, since no objective responses were
Fig. 8. Quantitative PCR analysis of ATP7A, ATP7B and hCTR1 mRNA. The amount of mRNA was determined after incubation with cddp or dFdC alone, after preincubation for
24 h with cddp followed by 48 h coincubation with dFdC (preinc cddp), after preincubation for 24 h with dFdC followed by 48 h coincubation with cddp (preinc dFdC) or after
72 h coincubation of cddp and dFdC (coinc). The molar ratio of cddp: dFdC was 120:1 for NASS cells and 600:1 for SJNB8 cells. The results shown are the mean ± SD of three
independent experiments.
O.G. Besançon et al. / Cancer Letters 319 (2012) 23–30 29observed [35]. In a recent study, a dFdC–oxaliplatin combination
was administrated consecutively on the same day in a bi-weekly
schedule. This combination has an acceptable safety proﬁle with
limited activity in children with relapsed or refractory solid tumors
[36]. However, our in vitro results provide evidence that synergism
between cddp and dFdC was dependent on the administration se-
quence used and is more likely to occur when neuroblastoma cells
are exposed to dFdC prior to the administration of cddp.
In summary, favorable interactions between cddp and dFdC
could be achieved in 4 out of 5 neuroblastoma cell lines due to
the inhibition of the NER system by dFdC, a decreased expression
of ATP7A and increased formation of DNA platinum adducts.
Therefore, we feel that inclusion of dFdC into cddp-containing reg-
iments might be a promising new strategy for the treatment of
neuroblastoma.
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